Skip to main content
Bristol Myers SquibbIn development

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock

Source: Autobound Signal API · 117 signals tracked for Bristol Myers Squibb · updated

Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.

What happened

Bristol-Myers Squibb reported positive Phase 3 trial data for its investigational breast cancer drug candidate iza-brentuximab (Iza-bren).

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

GLP-1 agonists may have taken up most of the attention when it comes to game-changing drugs in the last couple of years, but the oncology landscape is heating up as well, and investors may see a transformation for some long-standing firms in the space. Bristol-Myers Squibb BMY recently announced that its investigational drug candidate iza-brentuximab (Iza-bren) demonstrated a reduction in the risk of progression or death in a breast cancer trial. The Phase 3 trial data comes at a crucial time for the firm as it faces the ongoing threats of a major patent cliff for its popular blood cancer drug Revlimid. At its peak, this drug commanded annual sales of nearly $13 billion, but that was in 2021, and generic competition has eroded those sales in the years since. Given that breast cancer is the largest oncology indication across the country, any drug that can meaningfully boost progression-free survival has the potential to become another multi-billion-dollar venture. The Potential Implications of the Iza-bren Trial Data The Iza-bren trial in question focused on patients with HER2-low and HER2-ultra low metastatic cancers, common types of breast cancers that represent up to about two-thirds of all metastatic breast cancer cases. Despite the prevalence of these cancers, they are currently underserved by existing therapies. The Phase 3 trial data showed a 59% reduction in the risk...

Keep reading with a free account

The rest of this article, and every signal for Bristol Myers Squibb, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
iza-brentuximab

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Oct 26, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/af4cf4ea-37fc-dc32-53f4-3cb560e5250e returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.

{
  "signal_id": "af4cf4ea-37fc-dc32-53f4-3cb560e5250e",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-26T17:50:00+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "url": "https://www.tradingview.com/news/marketbeat:884159bcd094b:0-bristol-myers-squibb-s-cancer-breakthrough-could-have-implications-beyond-its-own-stock/",
    "title": "Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock - TradingView",
    "excerpt": "GLP-1 agonists may have taken up most of the attention when it comes to game-changing drugs in the last couple of years, but the oncology landscape is heating up as well, and investors may see a transformation for some long-standing firms in the space. Bristol-Myers Squibb BMY recently announced that its investigational drug candidate iza-brentuximab (Iza-bren) demonstrated a reduction in the risk of progression or death in a breast cancer trial. The Phase 3 trial data comes at a crucial time for the firm as it faces the ongoing threats of a major patent cliff for its popular blood cancer drug Revlimid. At its peak, this drug commanded annual sales of nearly $13 billion, but that was in 2021, and generic competition has eroded those sales in the years since. Given that breast cancer is the largest oncology indication across the country, any drug that can meaningfully boost progression-free survival has the potential to become another multi-billion-dollar venture. The Potential Implications of the Iza-bren Trial Data The Iza-bren trial in question focused on patients with HER2-low and HER2-ultra low metastatic cancers, common types of breast cancers that represent up to about two-thirds of all metastatic breast cancer cases. Despite the prevalence of these cancers, they are currently underserved by existing therapies. The Phase 3 trial data showed a 59% reduction in the risk of...",
    "product": "iza-brentuximab",
    "summary": "Bristol-Myers Squibb reported positive Phase 3 trial data for its investigational breast cancer drug candidate iza-brentuximab (Iza-bren).",
    "planning": false,
    "image_url": "https://s.tradingview.com/static/images/illustrations/news-story.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "iza-brentuximab",
      "full_text": "investigational drug candidate iza-brentuximab (Iza-bren)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-26T17:50:00Z",
    "article_sentence": "Bristol-Myers Squibb BMY recently announced that its investigational drug candidate iza-brentuximab (Iza-bren) demonstrated a reduction in the risk of progression or death in a breast cancer trial."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.